FDA approves N-Methanocarbathymidine as orphan drug in U.S
Release Date: 05-Oct-2016
NandN Pharmaceuticals Inc., an upcoming pharmaceuticals company announces N -Methanocarbathymidine receives orphan drug designation for the treatment of neonatal herpes simplex, by FDA.
Almost 25 % of all the pregnant women are seropositive for HSV-2, therefore, 85% of the neonates which are born with HSV-2 infection have one year mortality even with aggressive treatment. Despite of proper treatments the disease may cause death due to presence of virus-associated encephalitis and neutropenia.
For Orphan Drug Clinical Insight Reports Contact: email@example.com
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.